Research and Development

Boehringer Ingelheim has begun two new phase II trials of its investigational cancer drug afatinib. The studies will cover afatinib’s …

On Thursday 1st September a new version of the validation criteria for electronic submissions for human medicines will come into …

Private equity firm the Carlyle Group is rumoured to be looking at buying PPD, plus there are updates from CTA/Clininvent, …

Troy Norris has joined Quintiles as vice president and managing director for the product development and commercialisation practice at its …

Research into dementia, cancer, diabetes and heart disease are among the activities to benefit from a new £800 government funding …

GlaxoSmithKline has taken a £1.3 million stake in a new UK biotech spin-out that will develop pharmacological treatments for hearing …

Over recent years compliance with GMP in the manufacture of active substances (APIs) has been the subject of increasing regulatory …

Sanofi Pasteur MSD has appointed Dr Aidrian Kilcoyne as medical director in the UK. He joins the company from Roche …

Our round-up of news from the contract research sector includes the rejection of a cancer drug by the FDA because …

Of the $1.2 trillion spent globally each year on R&D across corporations and academia, 40 per cent – much the …

India’s Ipca Laboratories has bought UK chemistry services firm Onyx Scientific for around £4.6 million ($7.5m). The Mumbai-based company, a …

Astellas Pharma has appointed Dr Christopher Thomson as executive director of its new European Oncology Unit.   Dr Thomson will …

GlaxoSmithKline’s new drug IPX066 has helped Parkinson’s disease patients retain their motor skills after their medication wore off. IPX066, which …

New trials for MannKind’s investigational inhaled insulin drug Afrezza have been given the go-ahead by the FDA, potentially breathing new …

New genetic links to the immune system have been identified as a possible trigger for multiple sclerosis. The exact causes …